Assessment and treatment relevance in elderly glioblastoma patients

Neuro-Oncology

Volumn 16, Issue 11, 2014, Pages 1459-1468

  Bauchet, Luc ^a,b   Zouaoui, Sonia ^a,b   Darlix, Amélie ^b   De Champfleur, Nicolas Menjot ^c   Ferreira, Ernestine ^c   Fabbro, Michel ^a,b   Kerr, Christine ^b   Taillandier, Luc ^d  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b CENTRE VAL D AURELLE   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Assessment; Database; Elderly; Glioblastoma; Neuro oncology

Indexed keywords

AMINOLEVULINIC ACID; BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE;

AGED; ARTICLE; BRAIN BIOPSY; BRAIN SURGERY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; COMORBIDITY; DIAGNOSTIC IMAGING; DRUG TOLERANCE; GERIATRIC ASSESSMENT; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; PATIENT ASSESSMENT; PATIENT CARE; PATIENT SELECTION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; STANDARD; STEROID THERAPY; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

AGED; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; PROGNOSIS; QUALITY OF LIFE;

EID: 84927791924     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou063     Document Type: Article

References (87)

1. Reardon DA. Treatment of elderly patients with glioblastoma. Lancet Oncol. 2012;13(7):656-657.
2. Holdhoff M, Chamberlain MC. Controversies in the treatment of elderly patients with newly diagnosed glioblastoma. J Natl Compr Canc Netw. 2013;11(9):1165-1173.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.
5. Holdhoff M, Grossman SA. Controversies in the adjuvant therapy of high-grade gliomas. Oncologist. 2011;16(3):351-358.
6. Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;108(4):642-648.
7. Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol. 2013;15(6):797-805.
8. Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67(2):446-458.
9. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(suppl 5):v1-v49.
10. Rønning PA, Helseth E, Meling TR, et al. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol. 2012;14(9):1178-1184.
11. Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12(7):725-735.
12. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107(2):359-364.
13. Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628-634.
14. Gulati S, Jakola AS, Johannesen TB, et al. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg. 2012;78(5):518-526.
15. Chargari C, Feuvret L, Bauduceau O, et al. Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights. Cancer Treat Rev. 2012;38(8):988-995.
16. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013;15(8):1017-1026.
17. Batchelor TT, Betensky RA, Esposito JM, et al. Age-Dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10(1 Pt 1):228-233.
18. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
19. Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008;1:52.
20. McDonald KL, McDonnell J, Muntoni A, et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol. 2010;69(7):729-736.
21. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT Gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
22. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715.
23. Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol. 2011;102(2):311-316.
24. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.
25. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772.
26. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
27. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
28. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
29. Thon N, Kreth S, Kreth FW. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther. 2013;6:1363-1372.
30. Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118(22):5595-5600.
31. Zouaoui S, Darlix A, Fabbro-Peray P, et al. Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. [published online ahead of print February 14, 2014]. Neurosurg Rev. 2014; doi:10.1007/s10143-014-0528-8.
32. Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118(4):786-798.
33. Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg. 2011;114(3):587-594.
34. McGirt MJ, Mukherjee D, Chaichana KL, et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463-469.
35. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg. 1994;81(2):165-168.
36. Kim JE, Kim DG, Paek SH, et al. Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment. Acta Neurochir (Wien). 2003;145(7):547-554.
37. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527-1535.
38. Scott J, Tsai YY, Chinnaiyan P, et al. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2011;81(1):206-210.
39. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583-1588.
40. Beauchesne P, Bernier V, Carnin C, et al. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. Neuro Oncol. 2010;12(6):595-602.
41. Mayer R, Sminia P. Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys. 2008;70(5):1350-1360.
42. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-122.
43. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S20-S27.
44. Dinnes J, Cave C, Huang S, et al. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer. 2002;86(4):501-505.
45. Gállego Perez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29(22):3050-3055.
46. Yin AA, Cai S, Dong Y, et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J Neurooncol. 2014;116(2):315-324.
47. Yin AA, Zhang LH, Cheng JX, et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: A meta-Analysis. PLoS One. 2013;8(9):e74242.
48. Behm T, Horowski A, Schneider S, et al. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. Clin Neurol Neurosurg. 2013;115(10):2142-2146.
49. Brandes AA, Franceschi E. Primary brain tumors in the elderly population. Curr Treat Options Neurol. 2011;13(4):427-435.
50. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97-103.
51. Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70(4):987-992.
52. Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: Approach to the older cancer patient. Eur J Cancer. 2010;46(9):1502-1513.
53. Pallis AG, Ring A, Fortpied C, et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol. 2011;22(8):1922-1926.
54. Pontes Lde B, Karnakis T, Malheiros SM, et al. Glioblastoma: approach to treat elderly patients. Einstein (Sao Paulo). 2012;10(4):512-518.
55. Balducci L, Extermann M. Cancer and aging: An evolving panorama. Hematol Oncol Clin North Am. 2000;14(1):1-16.
56. Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur J Cancer. 1999;35(13):1771-1772.
57. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 1996;77(2):395-401.
58. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166-2172.
59. Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull. 1988;24(4):609-614.
60. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383.
61. Fiorentino A, Caivano R, Chiumento C, et al. Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma. Med Oncol. 2012;29(5):3467-3471.
62. Fiorentino A, Balducci M, De Bonis P, et al. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?. [published online ahead of print February 5, 2013]. Am J Clin Oncol. 2013; doi: 10.1097/COC.0b013e3182868ea2.
63. Tabouret E, Tassy L, Chinot O, et al. High-grade glioma in elderly patients: can the oncogeriatrician help?. Clin Interv Aging. 2013;8:1617-1624.
64. Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012;117(5):851-859.
65. Jafri NF, Clarke JL, Weinberg V, et al. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013;15(1):91-96.
66. Neal ML, Trister AD, Cloke T, et al. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patientspecific response metric. PLoS One. 2013;8(1):e51951.
67. Idema AJ, Hoffmann AL, Boogaarts HD, et al. 3'-Deoxy-3'-18F-Fluorothymidine PET-Derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med. 2012;53(12):1904-1910.
68. Barajas RF Jr, Hess CP, Phillips JJ, et al. Super-resolution track density imaging of glioblastoma: histopathologic correlation. AJNR Am J Neuroradiol. 2013;34(7):1319-1325.
69. Cortez-Conradis D, Favila R, Isaac-Olive K, et al. Diagnostic performance of regional DTI-derived tensor metrics in glioblastoma multiforme: simultaneous evaluation of p, q, L, Cl, Cp, Cs, RA, RD, AD, mean diffusivity and fractional anisotropy. Eur Radiol. 2013;23(4):1112-1121.
70. Ellingson BM, Cloughesy TF, Lai A, et al. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro Oncol. 2013;15(3):382-390.
71. Pope WB, Lai A, Mehta R, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882-889.
72. Romano A, Calabria LF, Tavanti F, et al. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol. 2013;23(2):513-520.
73. Gutman DA, Cooper LA, Hwang SN, et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013;267(2):560-569.
74. Zinn PO, Sathyan P, Mahajan B, et al. A Novel Volume-Age-KPS (VAK) Glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 2012;7(8):e41522.
75. Muacevic A, Kreth FW. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J Neurol. 2003;250(5):561-568.
76. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
77. Vuorinen V, Hinkka S, Färkkilä M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5-10.
78. Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol. 2012;109(2):391-397.
79. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012;83(1):93-99.
80. Nghiemphu PL, Cloughesy T. Glioblastoma therapy in the elderly: one age does not fit all. Lancet Oncol. 2012;13(9):857-858.
81. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39(4):350-357.
82. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus Irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729.
83. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent Bevacizumab followed by Bevacizumab plus Irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
84. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with Irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
85. Rigau V, Zouaoui S, Mathieu-DaudéH, et al. French Brain Tumor DataBase: 5-Year histological results on 25 756 Cases. Brain Pathol. 2011;21(6):633-644.
86. Zouaoui S, Rigau V, Mathieu-DaudéH, et al. French brain tumor database: general results on 40, 000 cases, main current applications and future prospects. Neurochirurgie. 2012;58(1):4-13.
87. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1):113-122.